COVID-19：卫材联合开发治疗药物：利用Elytran和E6011

COVID-19：卫材联合开发治疗药物：利用Elytran和E6011

-签订了共同的研究开发合同，开始了非临床研究活动-

卫材

COVID-19加重措施：

据报道，许多COVID-19患者由于急性呼吸窘迫综合征（ARDS）和多器官衰竭而变得严重。

阐明加重机制：

在这种恶化的过程中，假定血管疾病的形成和加剧以及细胞因子风暴*的参与。

然而，此时，SARS-CoV-2感染和加重的机制尚未完全阐明。

卫材创作的功效评价：

在这项联合研究中，我们将建立SARS-CoV-2感染的非临床动物模型。

由Eisai创建，已经过测试

TLR（Toll样受体）4拮抗剂，Elytran，
抗FKN（fractalkine）抗体药物E6011
我们将评估所用药物的功效。

生物标志物搜索：

此外，我们将促进使用源自SARS-CoV-2感染患者的临床样本搜索生物标志物。

通过这项联合研究，我们旨在阐明COVID-19加重的机制并开发药物来预防这种情况。

新闻发布：2020年|卫材

https://www.eisai.co.jp/news/2020/news202062.html

Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded

Eisai Co., Ltd.
announced today that it has entered into a joint research agreement with

four research organizations

KAN Research Institute,

Center for Global Health and Medicine,

Nagasaki University,

Yokohama City University in Japan

concerning the “Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)” (Grant Number: 20fk0108255),

which is a research project with Eisai as the representative research organization.

This joint research project “Development of Therapeutics for Novel Coronavirus Infectious Disease (COVID-19)”

was adopted for the second public call by the Japan Agency for Medical Research and Development (AMED) as part of its operation for promotion of the research and development of innovative treatments for emerging and re-emerging infectious diseases in fiscal year 2020.

In patients with COVID-19
due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported.

The involvement of the formation and exacerbation of vasculopathy as well as the cytokine storm* in the process of aggravation are assumed.

However, at this time, the mechanism of aggravation based on the SARS-CoV-2 infection is not fully understood.

In this collaborative research,
a non-clinical animal model of SARS-CoV-2 infection will be constructed.

Additionally, TLR (Toll-Like Receptor) 4 antagonist eritoran, discovered by Eisai,

and

an anti-FKN (fractalkine) antibody E6011, discovered by Eisai’s research subsidiary KAN Research Institute,

will be evaluated. In addition, this project will promote biomarker research using clinical samples derived from SARS-CoV-2 infected patients.

https://www.trialsitenews.com/eisai-joint-development-agreement-aiming-for-drug-discovery-for-covid-19-utilizing-eritoran-and-e6011-concluded/

More from tokioX :